Keyphrases
Bevacizumab
100%
Temozolomide
100%
Irinotecan
100%
Recurrent Glioblastoma
100%
Triple Therapy
100%
Tumor Treating Fields
100%
Recurrent GBM
71%
Progression-free Survival
57%
Overall Survival
42%
Chemotherapy
28%
Median Overall Survival
28%
T-group
28%
Pediatric
14%
Monotherapy
14%
Solid Tumors
14%
Hypertension
14%
Glioblastoma
14%
Salvage Chemotherapy
14%
Group-based
14%
Leukopenia
14%
Large Sample Size
14%
Field Treatment
14%
Drug Regimen
14%
Median Progression-free Survival
14%
Survival Disparities
14%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Retrospective Study
100%
Bevacizumab
100%
Irinotecan
100%
Temozolomide
100%
Glioblastoma
100%
Neoplasm
100%
Overall Survival
71%
Progression Free Survival
71%
Chemotherapy
42%
Side Effect
28%
Prospective Study
14%
Clinical Study
14%
Lomustine
14%
Solid Malignant Neoplasm
14%
Monotherapy
14%
Leukopenia
14%